Accessible Search Form           Advanced Search

9. Research Grants


NHLBI Research Grants by Funding Mechanism: Fiscal Year 2012

Research Project Grants (RPGs) Number of
Grants
Total Cost
(Dollars in Thousands)
Percent of
Total NHLBI
Research
Grant Dollars
Research Project Grants (Excluding Small Business RPGs)      
Regular Research Grants (R01) 2,773 $1,323,519 57.26%
Program Project Grants (P01) 149 313,862 13.58
Cooperative Agreements (U01) 191 222,452 9.62
Explorative Developmental Grant (R21) 304 63,479 2.75
Method to Extend Research in Time (R37) 70 30,973 1.34
Exploratory/Developmental Grants Phase II (R33) 4 2,843 0.12
Clinical Trial Planning Grant (R34) 27 8,883 0.38
Clinical Planning Grant Cooperative Agreement (U34) 4 2,101 0.09
Academic Research Enhancement Award (R15) 12 4,821 0.21
Research Transition Award (R00) 83 20,404 0.88
Cooperative Agreements (U19) 2 5,218 0.23
Small Research Grants (R03) 19 1,486 0.06
NIH Director's Pioneer Award (DP1) 3 2,252 0.10
Exploratory/Developmental Cooperative Agreements Phase I (UH2) 2 957 0.04
Multi-Component Research Project Cooperative Agreements (UM1) 10 13,259 0.57
Subtotal, Research Project Grants (Excluding Small Business RPGs) 3,653 2,016,509 87.23
Small Business Research Project Grants      
Small Business Technology Transfer (STTR Phase I) (R41) 15 5,095 0.22
Small Business Technology Transfer (STTR Phase II) (R42) 10 4,574 0.20
Small Business Innovation Research (SBIR Phase I) (R43) 75 18,942 0.82
Small Business Innovation Research (SBIR Phase II) (R44) 67 47,362 2.05
Subtotal, Small Business Research Project Grants 167 75,973 3.29
Subtotal, Research Project Grants 3,820 2,092,482 90.52
Research Centers Grants      
Centers of Research Programs (P50) 30 34,162 1.48
Specialized Centers (Cooperative Agreements) (U54) 2 8,142 0.35
Translational Research Centers in Thrombotic and Hemostatis Disorders (U54) 5 11,442 0.49
National Swine Research and Resource Center (U42) 1,440 0.06
Animal Model and Biological Material Resource Grants (U40) 1 903 0.04
Anchoring Metabolomic Changes to Phenotype (P20) 4 2,899 0.13
Centers for AIDS Research (P30) 3,428 0.15
Center Core Grants (P30) 5 1,019 0.04
Subtotal, Research Centers Grants 47 63,435 2.55
Research Career Programs      
Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01) 46 5,891 0.25
Mentored Career Award for Faculty at Minority Serving Institutions (K01) 4 546 0.02
Mentored Scientist Development Award in Research Ethics (K01) 67
Independent Scientist Award (K02) 17 1,653 0.07
Innovators in Hemoglobinopathies Care Career Development Award (K07) 2 533 0.02
Clinical Investigator Scientist Award (K08) 189 24,514 1.06
Clinical Hematology Research Career Development Program (K12) 6 2,325 0.10
Genetics and Genomics of Lung Disease Career Development Program (K12) 8 2,244 0.10
Career Development in Vascular Medicine Research Program (K12) 6 959 0.04
Clinical Research Career Development Programs in Emergency Medicine (K12) 6 3,065 0.13
Career Enhancement Award for Stem Cell Research (K18) 3 392 0.02
Career Transition Award (K22) 3 700 0.03
Mentored Patient-Oriented Research Career Development Award (K23) 164 23,027 1.00
Midcareer Investigator Award in Patient-Oriented Research (K24) 36 6,079 0.26
Mentored Quantitative Research Career Development Award (K25) 16 2,304 0.10
Career Transition Award (K99) 56 5,877 0.25
Subtotal, Research Career Programs 562 80,176 3.47
Other Research Grants      
Cooperative Clinical Research (U10, R10) 59 46,075 1.99
Minority Biomedical Research Support (S06, SC1, SC2) 10 2,199 0.10
Other (D43, R13, R18, R24, R25, T15, U24, UH1) 110 27,161 1.18
Subtotal, Other Research Grants 179 75,435 3.26
Total, NHLBI Research Grants 4,608 $2,311,529 100%


NHLBI Total Research Grants by Category

NHLBI Total Research Grants by Category
Text-only with data points

NHLBI Research Project Grant, Research Centers Grants, and Other Research Grant Obligations: Fiscal Years 2002–2012

NHLBI Research Project Grant, Research Centers Grant, and Other Research Grant Obligations
Text-only with data points are represented in the table below.

* Includes R01, U01, P01, R03, R15, R21, R29, R33, R37, R41, R42, R43, and R44; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.
**Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Research Project Grants, Research Centers Grants, and Other Research Grant Obligations: Fiscal Years 2002–2012

Dollars (Thousands)

 

FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011 FY 2012
Research Project Grants*

$1,779,573 $1,920,201 $2,003,769 $2,042,050 $2,011,049 $1,986,692 $1,983,633 $2,039,861 $2,108,524 $2,079,920 $2,092,482
Research Centers Grants

128,161 138,941 140,600 151,495 141,086 141,034 107,393 90,152 72,566 55,931 63,436
Other Research Grants**

98,460 113,172 112,785 116,713 123,802 135,284 125,942 131,001 129,245 152,772 155,661
Total $2,006,194 $2,172,314 $2,257,154 $2,310,258 $2,275,937 $2,263,010 $2,216,968 $2,261,014 $2,310,335 $2,288,623 $2,311,529

*R01, U01, P01, R03, R15, R21, R29, R33, R37, R41, R42, R43, and R44; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.
** Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Competing Research Project Grant Applications:* Fiscal Years 2002–2012

Number Reviewed and Awarded

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 2002-2012, Number Reviewed and Awarded
Text-only with data points are represented in the table below.

Number Reviewed and Awarded and Percent Funded

 

FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 2011 2012
Applications Reviewed 3,064 3,098 3,548 3,865 4,412 4,504 4,492 4,373 4,528 4,931 5,211
Applications Awarded 1,018 1,064 1,034 909 871 943 997 968 903 856 768
Percent Funded (Success Rate) 33.2 34.3 29.1 23.5 19.7 20.9 22.2 22.1 19.9 17.4 14.7

* Includes R01, U01, P01, R03, R15, R21, R29, R33, and R37; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.

Percent of Reviewed Applications Funded (Success Rate)

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 2002-2012, Percent of Reviewed Applications Funded (Success Rate)
Text-only with data points are represented in the table above.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 2002–2012

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 2002-2012
Text-only with data points are represented in the table below.

* Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research..
**Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 2002–2012

Dollars (Millions)

 

FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011 FY 2012
Investigator-Initiated* $1,584.9 $1,681.9 $1,773.4 $1,822.9 $1,802.1 $1,774.8 $1,820.8 $1,850.1 $1,950.9 $1,921.9 $1,892.2
Institute-Initiated** 421.3 490.4 483.8 487.3 473.8 488.2 396.1 410.9 359.5 366.7 419.3
Total $2,006.2 $2,172.3 $2,257.2 $2,310.2 $2,275.9 $2,263.0 $2,216.9 $2,261.0 $2,310.4 $2,288.6 $2,311.5

*  Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research..
**Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Research Project Grants:*  Amount Funded by Type of Award, Fiscal Years 2002–2012

Dollars (Millions)

 

FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011 FY 2012
Competing                      
  New Competing $   291.2 $   285.5 $   290.5 $   270.0 $   242.9 $   330.9 $   314.2 $ 340.2 $ 330.5 $ 353.1 $314.8
  Renewal Competing 143.9 177.2 185.5 176.1 168.3 169.4 196.9 172.6 171.6 131.6 111.4
  Competing
  Supplements
2.3 1 1.3 1.7 0.4 1.7 0.3 0.3 0.2
Subtotal, Competing 437.4 463.7 477.3 447.8 411.6 500.3 512.8 513.1 501.8 484.7 426.4
Noncompeting                      
Subtotal, Noncompeting 1,281.3 1,390.3 1,454.9 1,520.0 1,527.0 1,486.4 1,470.8 1,526.8 1,606.7 1,595.2 2,092.4
Total, Competing and Noncompeting $1,718.7 $1,854.0 $1,932.2 $1,967.8 $1,938.6 $1,986.7 $1,983.6 $2,039.9 $2,108.5 $2,079.9 $2,518.8

*Includes R01, U01, P01, R03, R15, R21, R29, R33, R37, R41, R42, R43, and R44; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011..

Facility and Administrative (F&A) Costs of NHLBI Research Project Grants:* Fiscal Years 2002–2012

Dollars (Thousands)

Fiscal Year Direct Cost F&A Cost Total Cost F&A Cost as a
Percent of Direct Cost
2002 1,182,408 536,324 1,718,732 45.4
2003 1,276,819 577,131 1,853,950 45.2
2004 1,329,106 603,133 1,932,239 45.4
2005 1,355,803 612,007 1,967,810 45.1
2006 1,334,406 604,183 1,938,589 45.3
2007 1,378,134 608,558 1,986,692 44.2
2008 1,376,276 607,357 1,983,633 44.1
2009 1,410,033 629,828 2,039,861 44.7
2010 1,459,211 649,313 2,108,524 44.5
2011 1,429,935 649,985 2,079,920 45.5
2012 1,450,958 641,524 2,092,482 44.2

* Includes R01, U01, P01, R03, R15, R21, R29, R33, R37, R41, R42, R43, and R44; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 2002–2012

NHLBI Research Project Grants*:  Average Costs, Fiscal Years 2002-2012
Text-only with data points are represented in the table below.

* Includes R01, U01, P01, R03, R15, R21, R29, R33, R37, R41, R42, R43, and R44; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 2002–2012

Dollars (Thousands)

 

FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011 FY 2012
Noncompeting $418.8 $444.4 $458.7 $490.6 $503.9 $510.3 $512.4 $509.8 $532.2 $538.6 $547.8
Competing 409.1 406.7 419.7 459.9 458.1 477.8 462.0 478.2 497.9 504.9 479.2
Total $416.2 $433.8 $447.9 $484.8 $492.8 $501.7 $501.8 $501.4 $523.6 $530.3 $530.3

* Includes R01, U01, P01, R03, R15, R21, R29, R33, R37, R41, R42, R43, and R44; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011.

NHLBI Cooperative Agreements (U01, U10, U19) Programs

Cooperative Agreements were instituted to support discrete, circumscribed projects in areas of an investigator’s spe­cific interest and competency with substantial programmatic participation by the NHLBI during performance of the activity.

 

Total Obligations Prior to FY 2012 Total FY 2012 Obligations Total Obligations to Date
Heart and Vascular Diseases      
ARIC Neurocognitive Study (ARIC-NCS) $9,156,680 $783,518 $9,940,198
Cardiovascular Cell Therapy Research Network 28,219,327 8,061,825 36,281,152
Cardiovascular Inflammation Reduction Trial (CIRT) 1,375,726 9,607,234 10,982,960
Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) 28,856,425 2,881,799 31,738,224
Catheter Ablation Versus Antiarrythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial 9,018,518 3,015,483 12,034,001
Center for Cardiovascular Outcomes Research 10,168,525 3,542,609 13,711,134
Childhood Obesity Prevention and Treatment Research (COPTR) 8,044,862 7,527,535 15,572,397
Claudication Exercise Versus Endoluminal Revascularization (CLEVER) 9,018,723 542,213 9,560,936
Consortium of Hospitals Advancing Research on Tobacco (CHART) 6,826,745 4,579,884 11,406,629
Cross Organ Mechanism-Associated Phenotypes for Genetic Analysis of Heart, Lung, Blood, and Sleep Diseases (MAPGen for HLBS) Research Centers 4,275,465 4,193,398 8,468,863
Diabetes Prevention Program Outcomes Study—Phase II 3,300,000 2,425,500 5,725,500
Early Adult Reduction of Weight Through LifestYle Intervention (EARLY) Trials* 16,643,216 4,857,967 21,501,183
Heart Failure Clinical Research Network 44,760,674 6,460,152 51,220,826
ISCHEMIA (International Study of Comparative Health Effectiveness With Medical Invasive Approaches) Trial 6,671,629 17,444,758 24,116,387
Look AHEAD:  Action for Health in Diabetes 12,000,000 4,000,000 16,000,000
Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine 31,438,403 7,097,239 38,535,642
Next Generation Genetic Association Studies 5,855,804 10,419,521 16,275,325
NHLBI Cardiac Development Consortium 15,276,752 6,978,522 22,255,274
NHLBI Pediatric Cardiac Genomics Consortium 8,957,755 3,977,556 12,935,311
NHLBI Pediatric Translational Consortium Administrative Coordinating Center 10,453,976 7,394,468 17,848,444
NHLBI Progenitor Cell Biology Consortium Research Hubs 69,302,980 26,196,688 95,499,668
Obesity Related Behavioral Intervention Trials (ORBIT)** 15,284,679 4,548,578 19,833,257
PDE5 Inhibition With Tadalafil Changes Outcomes in Heart Failure (PITCH-HF) 1,422,791 1,422,791
Pediatric Heart Network 76,176,050 12,249,798 88,425,848
Pharmacogenetics Research Network 80,953,760 6,498,845 87,452,605
Ranolazine in Implantable Defibrillators (RAID) Trial 2,279,794 2,287,927 4,567,721
Reducing the Impact of Hypertension in Low and Middle Income Countries 1,258,006 1,258,006
Resuscitation Outcomes Consortium (ROC) 55,902,830 7,923,746 63,826,576
Rule Out Myocardial Infarction Using Computed Assisted Tomography (ROMICAT II) 4,785,713 1,105,318 5,891,031
Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) Trials 10,395,495 4,370,676 14,766,171
Subtotal, Heart and Vascular Diseases 585,400,506 183,653,554 769,054,060
Lung Diseases      
Asthma Networks (AsthmaNet) 39,300,000 16,578,341 55,878,341
Genomic Research in AAT-Deficiency and Sarcoidosis Study (GRADS) 3,204,534 3,204,534
Heart and Lung Failure-Pediatric Insulin Titration Trial (HALF-PINT) 2,685,460 2,548,137 5,233,597
Lung Repair and Regeneration Consortium 4,910,973 4,910,973
Microbiome of the Lung and Respiratory Tract in HIV-Infected and in HIV-Uninfected Controls 16,067,661 5,289,811 21,357,472
Novel Therapies for Lung Diseases—Phase II 20,436,977 15,477,541 35,914,518
Pharmacogenetics of Asthma Treatment 30,955,719 1,958,575 32,914,294
Prematurity and Respiratory Outcomes Program (PROP) 5,664,228 4,119,773 9,784,001
Preterm Birth in Nulliparous Women:  An Understudied Population at Great Risk 3,798,000 668,815 4,466,815
Randomized Trial of Antenatal Late Preterm Steroids (ALPS) 4,271,361 556,659 4,828,020
Randomized Trial of Maternal Vitamin D Supplementation To Prevent Childhood Asthma 7,445,255 2,505,636 9,950,891
Sedation Management in Pediatric Patients With Acute Respiratory Failure 9,960,315 384,556 10,344,871
Severe Asthma Research Program 5,159,933 6,066,314 11,226,247
Study of Asthma and Nasal Steroids (STAN) 2,174,420 724,801 2,899,221
Study of Soy Isoflavones in Asthma (SOYA) 2,106,527 687,123 2,793,650
Trial of Late Surfactant (TOLSURF) To Prevent Bronchopulmonary Dysplasia (BPD) 5,572,999 1,653,180 7,226,179
Subtotal, Lung Diseases 155,598,855 67,334,769 222,933,624
Blood Diseases and Resources      
Acute Venous Thrombosis:  Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (ATTRACT) 6,516,312 2,459,244 8,975,556
Blood and Marrow Transplant Clinical Research Network 64,390,805 4,051,982 68,442,787
Bridging Anticoagulation on Patients Requiring Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) Trial 15,531,903 15,531,903
Transfusion-Associated Brain Improvement (TABI) Trial 1,729,189 1,729,189
Transfusion Medicine/Hemostasis Clinical Research Network 63,173,772 5,902,779 69,076,551
Subtotal, Blood Diseases and Resources 149,612,792 14,143,194 163,755,986
Total, NHLBI Cooperative Agreements $890,612,153 $265,131,517 $1,155,743,670

*    Formerly known as Targeted Approaches to Weight Control for Young Adults.
**  Formerly known as Translating Basic Behavior and Social Science Discoveries Into Interventions to Reduce Obesity.
Formerly known as Clinical Research Consortium To Improve Resuscitation Outcomes.
Formerly known as Pharmacomechanical Catheter-Directed Thrombolysis for Acute DVT (ATTRACT) Trial.

Back to Top

Heart and Vascular Diseases Program

ARIC Neurocognitive Study (ARIC-NCS), Initiated in Fiscal Year 2010

The purpose of this study is to determine whether mid-life vascular risk factors and markers of macrovascular and microvascular disease are predictive of dementia, mild cognitive impairment, and cognitive change in a large biracial ARIC cohort. 

Obligations

Funding History:
Fiscal Year 2012—$783,518
Fiscal Years 2010–2011—$9,156,680
Total Funding to Date—$9,940,198

Current Active Organizations and Grant Numbers

  1. Johns Hopkins University
    Baltimore, Maryland —HL-096812
  2. University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina —HL-096814
  3. University of  North Carolina, Chapel Hill
    Chapel Hill, North Carolina —HL-096899
  4. University of Minnesota
    Minneapolis, Minnesota —HL-096902
  5. University of Mississippi Medical Center
    Jackson, Mississippi   —HL-096917

Cardiovascular Cell Therapy Research Network, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

Cardiovascular Inflammation Reduction Trial (CIRT), Initiated in Fiscal Year 2011

The purpose of this trial is to test the inflammatory hypothesis of atherothrombosis by evaluating whether low-dose methotrexate will reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among stable post-myocardial infarction patients with type 2 diabetes or metabolic syndrome—conditions with enhanced pro-inflammatory response. 

Obligations

Funding History:
Fiscal Year 2012—$9,607,234
Fiscal Year 2011—$1,375,726
Total Funding to Date—$10,982,960

Current Active Organizations and Grant Numbers

  1. Brigham and Women's Hospital
    Boston, Massachusetts    —HL-101389
  2. Brigham and Women's Hospital
    Boston, Massachusetts    —HL-101422

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), Initiated in Fiscal Year 2004

The purpose of this trial is to determine whether renal artery stenting adds value to optimal medical therapy in terms of cardiovascular and renal outcomes in individuals with a history of resistant hypertension and/or chronic kidney disease and stenosis (>60%) of one or both renal arteries. 

Obligations

Funding History:
Fiscal Year 2012—$2,881,799
Fiscal Years 2004–2011—$28,856,425
Total Funding to Date—$31,738,224

Current Active Organizations and Grant Numbers

  1. University of Toledo Health
    Sciences Campus
    Toledo, Ohio —HL-071556
  2. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HL-072734
  3. Mid-America Heart Institute of
    St. Luke Hospital
    Kansas City, Missouri —HL-072736
  4. Beth Israel Deaconess Medical Center
    Boston, Massachusetts   —HL-072737

Catheter Ablation Versus Antiarrythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial, Initiated in Fiscal Year 2009

The purpose of this trial is to determine whether percutaneous left atrial catheter ablation is superior to current pharmacologic therapy for eliminating atrial fibrillation. 

Obligations

Funding History:
Fiscal Year 2012—$3,015,483
Fiscal Years 2009–2011—$9,018,518
Total Funding to Date—$12,034,001

Current Active Organizations and Grant Numbers

  1. Mayo Clinic, College of Medicine
    Rochester, Minnesota —HL-089645
  2. Mayo Clinic, College of Medicine
    Rochester, Minnesota —HL-089709
  3. Duke University
    Durham, North Carolina —HL-089786
  4. Duke University
    Durham, North Carolina —HL-089907

Center for Cardiovascular Outcomes Research, Initiated in Fiscal Year 2010

The purpose of this program is to conduct cardiovascular outcomes research that focuses on patient- and clinician-relevant outcomes of health care and their determinants. The goal is to move clinical evidence into public policy and clinical practice. 

Obligations

Funding History:
Fiscal Year 2012—$3,542,609
Fiscal Years 2010–2011—$10,168,525
Total Funding to Date—$13,711,134

Current Active Organizations and Grant Numbers

  1. University of Massachusetts Medical School
    Worcester, Massachusetts —HL-105268
  2. Yale University
    New Haven, Connecticut   —HL-105270
  3. Duke University
    Durham, North Carolina —HL-107023

Childhood Obesity Prevention and Treatment Research (COPTR), Initiated in Fiscal Year 2010

See Chapter 11. Clinical Trials.

Claudication:  Exercise Versus Endoluminal Revascularization (CLEVER), Initiated in Fiscal Year 2005

The purpose of this study is to optimize physical functioning, increase activity levels, and reduce CVD risk in older individuals with peripheral artery disease. Investigators are determining whether aortoiliac stenting and pharmacotherapy improve maximum walking duration better than supervised rehabilitation, exercise, and pharmacotherapy for those with moderate to severe claudication due to aortoiliac insufficiency. 

Obligations

Funding History:
Fiscal Year 2012—$542,213
Fiscal Years 2005–2011—$9,018,723
Total Funding to Date—$9,560,936

Current Active Organizations and Grant Numbers

  1. Rhode Island Hospital
    Providence, Rhode Island  —HL-077221
  2. Beth Israel Deaconess Medical Center
    Boston, Massachusetts   —HL-081656

Consortium of Hospitals Advancing Research on Tobacco (CHART), Initiated in Fiscal Year 2010

See Chapter 11. Clinical Trials.

Cross Organ Mechanism-Associated Phenotypes for Genetic Analysis of Heart, Lung, Blood, and Sleep Diseases (MAPGen for HLBS) Research Centers, Initiated in Fiscal Year 2011

The purpose of this program is to establish a MAPGen consortium of research centers. The consortium seeks to define common mechanism-associated traits across organ systems and to redefine disease by pathogenetic mechanisms and phenotype individuals based on pathobiology, rather than clinical presentation. This approach will provide the basis for the development of mechanism-based strategies for prevention, diagnosis, and treatment in individual patients. 

Obligations

Funding History:
Fiscal Year 2012—$4,193,398
Fiscal Year 2011—$4,275,465
Total Funding to Date—$8,468,863

Current Active Organizations and Grant Numbers

  1. Brigham and Women's Hospital
    Boston, Massachusetts   —HL-108630
  2. University of Southern California
    Los Angeles, California   —HL-108634
  3. University of Pennsylvania
    Philadelphia, Pennsylvania  —HL-108636
  4. Yale University
    New Haven, Connecticut   —HL-108638
  5. University of Pittsburgh
    Pittsburgh, Pennsylvania    —HL-108642
  6. Stanford University
    Menlo Park, California   —HL-108647

Diabetes Prevention Program Outcomes Study—Phase II, Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials

Early Adult Reduction of Weight Through LifestYle Intervention (EARLY) Trials,* Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials.

*  Formerly known as Targeted Approaches to Weight Control for Young Adults. 

Heart Failure Clinical Research Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials

ISCHEMIA (International Study of Comparative Health Effectiveness With Medical Invasive Approaches) Trial, Initiated in Fiscal Year 2011

The purpose of this trial is to determine whether optimal medical therapy plus cardiac catheterization followed by complete revascularization is superior to optimal medical therapy alone as the management strategy for patients with moderate-severe ischemia on stress imaging. Cost-effectiveness will also be assessed. 

Obligations

Funding History:
Fiscal Year 2012—$17,444,758
Fiscal Year 2011—$6,671,629
Total Funding to Date—$24,116,387

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina —HL-105462
  2. Emory University
    Atlanta, Georgia —HL-105561
  3. Duke University
    Durham, North Carolina —HL-105565
  4. New York University School of Medicine
    New York, New York —HL-105907

Look AHEAD:  Action for Health in Diabetes, Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials

Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

Next Generation Genetic Association Studies, Initiated in Fiscal Year 2011

The purpose of this study is to investigate functional aspects of genetic variation in humans by combining cellular reprogramming strategies with molecular profiling or cellular assays, and then integrating the information with existing genotypic and clinical phenotypic data to assess how naturally occurring human genetic variation influences the activities of biological networks in cell-based models of disease. Researchers are seeking to develop the technology needed for high-throughput iPS cell line generation and differentiation and will use the technology to follow up on genomic associations with additional mechanistic information gained from cellular models of disease. 

Obligations

Funding History:
Fiscal Year 2012—$10,419,521
Fiscal Year 2011—$5,855,804
Total Funding to Date—$16,275,325

Current Active Organizations and Grant Numbers

  1. Stanford University
    Stanford, California —HL-107388
  2. Stanford University
    Stanford, California  —HL-107393
  3. Scripps Research Institute
    La Jolla, California    —HL-107436
  4. Medical College of Wisconsin
    Milwaukee, Wisconsin    —HL-107437
  5. Massachusetts General Hospital
    Boston, Massachusetts   —HL-107440
  6. University of California, San Diego
    La Jolla, California    —HL-107442
  7. Boston University Medical Campus
    Boston, Massachusetts   —HL-107443
  8. Johns Hopkins University
    Baltimore, Maryland   —HL-107446

NHLBI Cardiac Development Consortium, Initiated in Fiscal Year 2009

The purpose of this study is to elucidate the regulatory networks controlling cardiovascular development. A consortium of multidisciplinary research teams will select key regulatory pathways, identify components of the pathways and targets, and disseminate data to the scientific community. Research results may lead to the development of regenerative therapies and tissue engineering approaches. 

Obligations

Funding History:
Fiscal Year 2012—$6,978,522
Fiscal Years 2009–2011—$15,276,752
Total Funding to Date—$22,255,274

Current Active Organizations and Grant Numbers

  1. University of Utah
    Salt Lake City, Utah  —HL-098160
  2. Harvard University Medical School
    Boston, Massachusetts   —HL-098166
  3. J. David Gladstone Institutes
    San Francisco, California   —HL-098179
  4. University of Pittsburgh
    Pittsburgh, Pennsylvania    —HL-098180

NHLBI Pediatric Cardiac Genomics Consortium, Initiated in Fiscal Year 2009

The purpose of this study is to conduct clinical and translational research on genetic causes of congenital heart disease and genetic contributions to outcomes in individuals with congenital heart disease. 

Obligations

Funding History:
Fiscal Year 2012—$3,977,556
Fiscal Years 2009–2011—$8,957,755
Total Funding to Date—$12,935,311

Current Active Organizations and Grant Numbers

  1. Mount Sinai School of Medicine
    New York, New York —HL-098123
  2. Children's Hospital Boston
    Boston, Massachusetts   —HL-098147
  3. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania  —HL-098153
  4. Yale University
    New Haven, Connecticut   —HL-098162
  5. Columbia University Health Sciences
    New York, New York —HL-098163

NHLBI Pediatric Translational Consortium Administrative Coordinating Center, Initiated in Fiscal Year 2009

The purpose of this Coordinating Center is to provide administrative support for the Cardiovascular Development Consortium and the Pediatric Cardiac Genomics Consortium, monitor multicenter patient recruitment by the Pediatric Cardiac Genomics Consortium, and administer funds to consortium-wide cores. 

Obligations

Funding History:
Fiscal Year 2012—$7,394,468
Fiscal Years 2009–2010—$10,453,976
Total Funding to Date—$17,848,444

Current Active Organization and Grant Number

  1. New England Research Institute, Inc. 
    Watertown, Massachusetts  —HL-98188

NHLBI Progenitor Cell Biology Consortium Research Hubs, Initiated in Fiscal Year 2009

The purpose of this study is to establish virtual research hubs that focus on progenitor cell biology. Investigators are seeking to identify and characterize progenitor cell lineages, direct differentiation of stem and progenitor cells to desired cell fates, and develop new strategies to address the unique challenges presented by the transplantation of progenitor cells. 

Obligations

Funding History:
Fiscal Year 2012—$26,196,688
Fiscal Years 2009–2011—$69,302,980
Total Funding to Date—$95,499,668

Current Active Organizations and Grant Numbers

  1. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania  —HL-099656
  2. Morgridge Institute for Research, Inc. 
    Madison, Wisconsin  —HL-099773
  3. Johns Hopkins University
    Baltimore, Maryland —HL-099775
  4. Stanford University
    Menlo Park, California   —HL-099776
  5. Fred Hutchinson Cancer Research Center
    Seattle, Washington   —HL-099993
  6. Stanford University
    Menlo Park, California   —HL-099995
  7. University of Maryland
    Baltimore, Maryland —HL-099997
  8. Stanford University
    Menlo Park, California   —HL-099999
  9. Children's Hospital Boston
    Boston, Massachusetts   —HL-100001
  10. Fred Hutchinson Cancer Research Center
    Seattle, Washington   —HL-100395
  11. Stanford University
    Stanford, California  —HL-100397
  12. Vanderbilt University
    Nashville, Tennessee —HL-100398
  13.  University of Texas Southwestern
    Medical Center
    Dallas, Texas    —HL-100401
  14. Massachusetts General Hospital
    Boston, Massachusetts   —HL-100402
  15. University of Pennsylvania
    Philadelphia, Pennsylvania  —HL-100405
  16. J. David Gladstone Institutes
    San Francisco, California   —HL-100406
  17. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HL-100407
  18. Massachusetts General Hospital
    Boston, Massachusetts   —HL-100408

Obesity Related Behavioral Intervention Trials (ORBIT),* Initiated in Fiscal Year 2009

The purpose of this study is to translate findings from basic research on human behavior into more effective clinical, community, and population interventions to reduce obesity and improve obesity-related behaviors. Investigators are seeking to develop innovative obesity-reducing strategies that are effective in small-scale trials, acceptable to target populations of interest, and are ready for testing in large-scale randomized clinical and community trials. Some of the projects are expected to have 50–100 percent participation from minority populations. 

Obligations

Funding History:
Fiscal Year 2012—$4,548,578
Fiscal Years 2009–2011—$15,284,679
Total Funding to Date—$19,833,257

Current Active Organizations and Grant Numbers

  1. Weill Medical College of
    Cornell University
    New York, New York —HL-097843
  2. Wayne State University
    Detroit, Michigan   —HL-097889
  3. Rush University Medical Center
    Chicago, Illinois  —HL-097894
  4. University of California, San Francisco
    San Francisco, California   —HL-097973

*  Formerly known as Translating Basic Behavioral and Social Sciences Discoveries Into Interventions To Reduce Obesity. 

PDE5 Inhibition With Tadalafil Changes Outcomes in Heart Failure (PITCH-HF)), Initiated in Fiscal Year 2012

The purpose of this study is to test the safety and efficacy of tadalafil, a pulmonary vasodilator and phosphodiesterase Type 5 (PDE5) inhibitor, in patients with heart failure and reduced left ventricular ejection fraction (LVEF), specifically an LVEF less than 40%, and secondary pulmonary hypertension. 

Obligations

Funding History:
Fiscal Year 2012—$1,422,791
Total Funding to Date—$1,422,791

Current Active Organizations and Grant Numbers

  1. Massachusetts General Hospital
    Boston, Massachusetts   —HL-105562
  2. New England Research Institute, Inc. 
    Watertown, Massachusetts  —HL-105563

Pediatric Heart Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Pharmacogenetics Research Network, Initiated in Fiscal Year 2001

The purpose of this program is to establish a network of multidisciplinary, collaborative research groups to study how genetic variation contributes to interindividual differences in responses to medications. Four studies under this initiative are investigating the pharmacogenetics of heart, lung, and blood diseases. One of the projects has 38 percent minority participation. The Pharmacogenetics Knowledgebase (PharmGKB) has been established to integrate information obtained from pharmacogenomics, phenotypes, and genotypes. 

Obligations

Funding History:
Fiscal Year 2012—$6,498,845
Fiscal Years 2001–2011—$80,953,760
Total Funding to Date—$87,452,605

Current Active Organizations and Grant Numbers

  1. Brigham and Women's Hospital
    Boston, Massachusetts   —HL-065899
  2. Vanderbilt University
    Nashville, Tennessee —HL-065962
  3. Children's Hospital and Research Center
    Oakland, California   —HL-069757
  4. University of Maryland
    Baltimore, Maryland —HL-105198

Ranolazine in Implantable Defibrillators (RAID) Trial, Initiated in Fiscal Year 2010

The purpose of this clinical trial is to determine whether ranolazine will reduce the risk of ventricular arrhythmias and improve survival in high-risk patients who already have an implantable cardiac defibrillator. Currently, very few options are available for treating patients at risk for ventricular arrhythmias—which often leads to death—and ranolazine may be a safe and effective treatment. 

Obligations

Funding History:
Fiscal Year 2012—$2,287,927
Fiscal Years 2010–2011—$2,279,794
Total Funding to Date—$4,567,721

Current Active Organizations and Grant Numbers

  1. University of Rochester
    Rochester, New York —HL-096607
  2. University of Rochester
    Rochester, New York —HL-096610

Reducing the Impact of Hypertension in Low and Middle Income Countries, Initiated in Fiscal Year 2012

The purpose of this study is to support effective interventions that will provide sound scientific evidence for expanding sustainable blood pressure prevention and control programs in low- and middle-income countries at the local, regional, and national levels. 

Obligations

Funding History:
Fiscal Year 2012—$1,258,006
Total Funding to Date—$1,258,006

Current Active Organizations and Grant Numbers

  1. Johns Hopkins University
    Baltimore, Maryland —HL-114180
  2. Tulane University of Louisiana
    New Orleans, Louisiana  —HL-114197
  3. New York University School of Medicine
    New York, New York —HL-114198
  4. Mount Sinai School of Medicine
    New York, New York  — HL-114200

Resuscitation Outcomes Consortium (ROC),* Initiated in Fiscal Year 2004

See Chapter 11. Clinical Trials.

Rule Out Myocardial Infarction Using Computed Assisted Tomography (ROMICAT II), Initiated in Fiscal Year 2009

The purpose of this study is to determine whether using cardiac computed assisted tomography early in the emergency department triage will enable immediate and safe discharge without further testing of a significant number of patients with acute chest pain. 

Obligations

Funding History:
Fiscal Year 2012—$1,105,318
Fiscal Years 2009–2011—$4,785,713
Total Funding to Date—$5,891,031

Current Active Organizations and Grant Numbers

  1. Massachusetts General Hospital
    Boston, Massachusetts   —HL-092022 
  2. Massachusetts General Hospital
    Boston, Massachusetts   —HL-092040

Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) Trials, Initiated in Fiscal Year 2009

The purpose of this program is to determine whether therapeutic hypothermia after pediatric cardiac arrest improves outcomes, including survival, in infants and children. Approximately 50 percent of the patients are expected to come from racial and ethnic minority populations. 

Obligations

Funding History:
Fiscal Year 2012—$4,370,676
Fiscal Years 2009–2011—$10,395,495
Total Funding to Date—$14,766,171

Current Active Organizations and Grant Numbers

  1. University of Utah
    Salt Lake City, Utah  —HL-094339
  2. University of Michigan
    Ann Arbor, Michigan —HL-094345

Lung Diseases Program

Asthma Networks (AsthmaNet), Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials.

Genomic Research in ATT-Deficiency and Sarcoidosis Study (GRADS), Initiated in Fiscal Year 2012

The purposes of this study are to identify molecular abnormalities in patients with alpha-1-antitrypsin deficiency (ATT) or sarcoidosis through genomic and microbiomic analyses and to determine the relationship of these abnormalities to the clinical characteristics of patients. Clinical studies will be conducted to elucidate pathogenetic mechanisms or to identify predictors of disease development and progression. Many of the projects will have at least 50-percent participation from minority populations. 

Obligations

Funding History:
Fiscal Year 2012—$3,204,534
Total Funding to Date—$3,204,534

Current Active Organizations and Grant Numbers

  1. Vanderbilt University
    Nashville, Tennessee —HL-112694
  2. National Jewish Health
    Denver, Colorado   —HL-112695
  3. University of California, San Francisco
    San Francisco, California   —HL-112696
  4. Yale University
    New Haven, Connecticut   —HL-112702
  5. University of Pittsburgh at Pittsburgh
    Pittsburgh, Pennsylvania    —HL-112707
  6. Johns Hopkins University
    Baltimore, Maryland —HL-112708
  7. University of Pittsburgh at Pittsburgh
    Pittsburgh, Pennsylvania    —HL-112711
  8. University of Pennsylvania
    Philadelphia, Pennsylvania  —HL-112712

Heart and Lung Failure-Pediatric Insulin Titration Trial (HALF-PINT), Initiated in Fiscal Year 2011

The purpose of this study is to determine whether safe and effective tight glycemic control can sufficiently reduce morbidity and mortality in children with heart and lung failure to justify a low risk of hypoglycemia. 

Obligations

Funding History:
Fiscal Year 2012—$2,548,137
Fiscal Year 2011—$2,685,460
Total Funding to Date—$5,233,597

Current Active Organizations and Grant Numbers

  1. Children's Hospital Boston
    Boston, Massachusetts   —HL-107681
  2. Children's Hospital Boston
    Boston, Massachusetts   —HL-108028

Lung Repair and Regeneration Consortium, Initiated in Fiscal Year 2012

The purpose of this consortium is to establish multidisciplinary teams of investigators, cutting edge technologies, innovative strategies, and new ideas to investigate novel hypotheses that are relevant to lung repair and regeneration in order to move the field of lung regeneration forward toward the development of new therapies for human diseases. 

Obligations

Funding History:
Fiscal Year 2012—$4,910,973
Total Funding to Date—$4,910,973

Current Active Organizations and Grant Numbers

  1. University of Pennsylvania
    Philadelphia, Pennsylvania  —HL-110942
  2. Children's Hospital Center Cincinnati
    Cincinnati, Ohio —HL-110964
  3. Duke University
    Durham, North Carolina —HL-110967
  4. Yale University
    New Haven, Connecticut   —HL-111016
  5. Duke University
    Durham, North Carolina —HL-111018
  6. University of California, San Francisco
    San Francisco, California   —HL-111054
  7. University of Texas Southwestern
    Medical Center
    Dallas, Texas    —HL-111146

Microbiome of the Lung and Respiratory Tract in HIV-Infected Individuals and HIV-Uninfected Controls, Initiated in Fiscal Year 2009

The purpose of this study is to characterize the microbiome of the lung alone or in combination with the upper airways in HIV-infected individuals and matched HIV-uninfected controls. Investigators are using molecular techniques to identify bacteria, and if possible, other organisms (e.g. , viruses, cell-wall deficient organisms, protozoa, and fungi). Data will be used to examine the effects of changes in the respiratory microbiome on the pathogenesis and progression of HIV disease, HIV-related respiratory complications, and anti-HIV therapies. 

Obligations

Funding History:
Fiscal Year 2012—$5,289,811
Fiscal Years 2009–2011—$16,067,661
Total Funding to Date—$21,357,472

Current Active Organizations and Grant Numbers

  1. University of Pennsylvania
    Philadelphia, Pennsylvania  —HL-098957
  2. George Washington University
    Washington, DC —HL-098958
  3. Indiana University-Purdue University,
    Indianapolis
    Indianapolis, Indiana  —HL-098960
  4. University of Michigan
    Ann Arbor, Michigan —HL-098961
  5. University of Pittsburgh
    Pittsburgh, Pennsylvania    —HL-098962
  6. University of California, San Francisco
    San Francisco, California   —HL-098964
  7. University of Colorado
    Denver, Colorado   —HL-098966

Novel Therapies for Lung Diseases—Phase II, Initiated in Fiscal Year 2010

See Chapter 11. Clinical Trials

Pharmacogenetics of Asthma Treatment, Initiated in Fiscal Year 2000

The objective of this project is to bring together research experts in asthma, epidemiology, statistics, bioinformatics, physiology, clinical trials, genetics, and genomics to focus on the pharmacogenetics of asthma treatment. 

Obligations

Funding History:
Fiscal Year 2012—$1,958,575
Fiscal Years 2000–2011—$30,955,719
Total Funding to Date—$32,914,294

Current Active Organization and Grant Number

  1. Brigham and Women's Hospital
    Boston, Massachusetts   —HL-065899

Prematurity and Respiratory Outcomes Program (PROP), Initiated in Fiscal Year 2010

The purpose of this observational clinical study is to investigate hypotheses on the molecular mechanisms that contribute to respiratory disease risk of the premature newborn with the long-term goal of improving outcomes in the first year of life. 

Obligations

Funding History:
Fiscal Year 2012—$4,119,773
Fiscal Years 2010–2011—$5,664,228
Total Funding to Date—$9,784,001

Current Active Organizations and Grant Numbers

  1. Vanderbilt University
    Nashville, Tennessee —HL-101456
  2. Washington University
    St. Louis, Missouri  —HL-101465
  3. University of Pennsylvania
    Philadelphia, Pennsylvania  —HL-101794
  4. University of California, San Francisco
    San Francisco, California   —HL-101798
  5. Children's Hospital Medical Center,
    Cincinnati
    Cincinnati, Ohio —HL-101800
  6. University of Rochester
    Rochester, New York —HL-101813

Preterm Birth in Nulliparous Women:  An Understudied Population at Great Risk, Initiated in Fiscal Year 2010

The purpose of this study is to create a network of clinical research sites with a Data Coordinating and Analysis Center to develop common research protocols to study the cardiovascular health of women in their first pregnancy and assess the significance of disordered breathing. 

Obligations

Funding History:
Fiscal Year 2012—$668,815
Fiscal Years 2010–2011—$3,798,000
Total Funding to Date—$4,466,815

Current Active Organization and Grant Number

  1. Research Triangle Institute
    Research Triangle, North Carolina   —HD-063069

Randomized Trial of Antenatal Late Preterm Steroids (ALPS), Initiated in Fiscal Year 2010

The purpose of this study is to determine whether antenatal corticosteroids can potentially improve lung function and reduce respiratory morbidity in newborn infants who are born in the late preterm period (34–36 weeks). Previous studies have shown that steroids improve lung function in very premature infants. Fifty-five percent of the participants are expected to come from racial and ethnic minority populations. 

Obligations

Funding History:
Fiscal Year 2012—$556,659
Fiscal Years 2010–2011—$4,271,361
Total Funding to Date—$4,828,020

Current Active Organizations and Grant Numbers

  1. George Washington University
    Washington, DC —HL-098354
  2. Columbia University Health Sciences
    New York, New York —HL-098554

Randomized Trial of Maternal Vitamin D Supplementation To Prevent Childhood Asthma, Initiated in Fiscal Year 2009

The purpose of this randomized clinical trial is to determine whether supplemental vitamin D to increase the level of vitamin D in a pregnant woman will prevent asthma and allergy in her child at age 3 years. Investigators will recruit 870 pregnant women who are in the first trimester of pregnancy and randomize them to one of two treatment arms of a 4-year clinical trial:  one arm being treatment with 4,000 international units of vitamin D in addition to typical prenatal vitamins and the other being treatment with typical prenatal vitamins alone. Currently, 80 percent of the participants are from racial and ethnic minority populations. 

Obligations

Funding History:
Fiscal Year 2012—$2,505,636
Fiscal Years 2009–2011—$7,445,255
Total Funding to Date—$9,950,891

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri  —HL-091075
  2. Brigham and Women's Hospital
    Boston, Massachusetts   —HL-091528

Sedation Management in Pediatric Patients With Acute Respiratory Failure, Initiated in Fiscal Year 2008

The purpose of this randomized clinical trial is to test an innovative approach to sedation management that includes team education and consensus on the use of sedatives in pediatric patients supported on mechanical ventilation; team identification of each patient's trajectory of illness and daily prescription of a sedation goal; use of a nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines; and team feedback on sedation management performance. Investigators have randomized 2,754 critically ill infants and children into two study groups:  sedation management intervention and usual care. Forty-five percent of the patients are from racial and ethnic minority populations. 

Obligations

Funding History:
Fiscal Year 2012—$384,556
Fiscal Years 2008–2011—$9,960,315
Total Funding to Date—$10,344,871

Current Active Organization and Grant Number

  1. Children's Hospital Boston
    Boston, Massachusetts   —HL-086649

Severe Asthma Research Program,* Initiated in Fiscal Year 2011

The purpose of this study is to define severe asthma at the molecular and cellular levels longitudinally to understand its evolution. Research findings will serve as a rational basis for designing mechanism-based diagnostic, prognostic, and treatment strategies for severe asthma. 

Obligations

Funding History:
Fiscal Year 2012—$6,066,314
Fiscal Year 2011—$5,159,933
Total Funding to Date—$11,226,247

Current Active Organizations and Grant Numbers

  1. Pennsylvania State University,
    Hershey Medical Center
    Hershey, Pennsylvania   —HL-109086
  2. University of California, San Francisco
    San Francisco, California   —HL-109146
  3. University of Pittsburgh
    Pittsburgh, Pennsylvania    —HL-109152
  4. Wake Forest University Health Sciences
    Winston-Salem, North Carolina —HL-109164
  5. University of Wisconsin, Madison
    Madison, Wisconsin —HL-109168
  6. Brigham and Women's Hospital
    Boston, Massachusetts   —HL-109172
  7. University of Virginia, Charlottesville
    Charlottesville, Virginia   —HL-109250
  8. Washington University
    St. Louis, Missouri —HL-109257

*    The Severe Asthma Research Program began in FY 2001 and was funded under the R01 mechanism.

Study of Asthma and Nasal Steroids (STAN), Initiated in Fiscal Year 2009

The purpose of this clinical trial is to determine whether treatment of chronic rhinitis and sinusitis with a nasal steroid improves asthma control. Investigators have randomized 380 patients with poorly controlled asthma and chronic rhinitis and sinusitis to a nasal steroid or matching placebo in addition to their regular asthma treatment. One third of participants are expected to be from minority populations. 

Obligations

Funding History:
Fiscal Year 2012—$724,801
Fiscal Years 2009–2011—$2,174,420
Total Funding to Date—$2,899,221

Current Active Organizations and Grant Numbers

  1. University of Vermont
    Burlington, Vermont  —HL-089464
  2. Johns Hopkins University
    Baltimore, Maryland —HL-089510

Study of Soy Isoflavones in Asthma (SOYA), Initiated in Fiscal Year 2009

The purpose of this double-blind, randomized con­trolled trial is to determine whether genistein supplements (soy isoflavone) improves lung func­tion in patients with poorly controlled asthma. The study includes 380 patients with low dietary soy intake, ages 12 years and older, who are taking either inhaled corticosteroids or leukotriene modifiers or both and have poorly controlled asthma. Participants are being randomly assigned to treatment with either a soy isoflavone supplement (containing genistein, daidzein, and glycitein) 100 mg daily or to placebo for 6 months. Thirty percent of participants are expected to be from minority populations. 

Obligations

Funding History:
Fiscal Year 2012—$687,123
Fiscal Years 2009–2011—$2,106,527
Total Funding to Date—$2,793,650

Current Active Organizations and Grant Numbers

  1. Northwestern University
    Evanston, Illinois   —HL-087987
  2. Johns Hopkins University
    Baltimore, Maryland —HL-088367

Trial of Late Surfactant (TOLSURF) To Prevent Bronchopulmonary Dysplasia, Initiated in Fiscal Year 2009

The purpose of this randomized controlled clinical trial is to determine whether late doses of surfactant in addition to iNO administered to extremely low gestational age neonates (< 30 weeks) who require mechanical ventilation between 7 and 14 days of age will increase survival without bronchopulmonary dysplasia. 

Obligations

Funding History:
Fiscal Year 2012—$1,653,180
Fiscal Years 2009–2011—$5,572,999
Total Funding to Date—$7,226,179

Current Active Organizations and Grant Numbers

  1. University of California, San Francisco
    San Francisco, California   —HL-094338
  2. University of California, San Francisco
    San Francisco, California   —HL-094355

Blood Diseases and Resources

Acute Venous Thrombosis:  Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (ATTRACT),* Initiated in Fiscal Year 2008

* Formerly known as Pharmacomechanical Catheter-Directed Thrombolysis for Acute DVT (ATTRACT) Trial.

The purpose of this study is to determine whether adjunctive pharmacomechanical catheter-directed thrombolysis (PCDT), which includes intrathrombus admin­­istration of recombinant tissue plasminogen activator, can prevent post-thrombotic syndrome in patients with symptomatic proximal deep vein thrombosis (DVT). Investigators are comparing the addition of PCDT to optimal standard DVT therapy with optimal standard DVT therapy alone. 

Obligations

Funding History:
Fiscal Year 2012—$2,459,244
Fiscal Years 2008–2011—$6,516,312
Total Funding to Date—$8,975,556

Current Active Organizations and Grant Numbers

  1. McMaster University
    Hamilton, Ontario  —HL-088118
  2. Washington University
    St. Louis, Missouri  —HL-088476

Blood and Marrow Transplant Clinical Research Network, Initiated in Fiscal Year 2001

See Chapter 11. Clinical Trials.

Bridging Anticoagulation on Patients Requiring Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) Trial, Initiated in Fiscal Year 2008

The purpose of this study is to determine the safety and efficacy of low molecular weight heparin (LMWH) in adults with atrial fibrillation who stop warfarin in preparation for surgery. The trial randomly allocated 3,282 patients with atrial fibrillation to either LMWH or placebo before and after surgery. Investigators hypothesize that simply withholding warfarin in a perioperative setting for patients with atrial fibrillation will not meaningfully increase the risk for arterial thromboembolism and will forestall hemorrhagic complications, compared with a strategy using LMWH before and after surgery. One-third of participants are expected to be from minority populations. 

Obligations

Funding History:
Fiscal Year 2012—$0
Fiscal Years 2008–2011—$15,531,903
Total Funding to Date—$15,531,903

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina —HL-086755
  2. Duke University
    Durham, North Carolina —HL-087229

Transfusion-Associated Brain Improvement (TABI) Trial, Initiated in Fiscal Year 2012

The purpose of this study is to determine whether higher hemoglobin thresholds for transfusing extremely low birth weight babies born at less than 1,000 grams increases survival and improves long-term neurodevelopment at 18–22 months of age. The TABI trial is partnering with the NICHD Neonatal Research network and its 18 clinical centers. 

Obligations

Funding History:
Fiscal Year 2012—$1,729,189
Total Funding to Date—$1,729,189

Current Active Organizations and Grant Numbers

  1. Research Triangle Institute
    Research Triangle, North Carolina   —HL-112748
  2. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania  —HL-112776

Transfusion Medicine/Hemostasis Clinical Research Network, Initiated in Fiscal Year 2002

See Chapter 11. Clinical Trials.

NHLBI Centers of Research Program (P50)

The Centers of Research Program supports specialized centers that focus on multidisciplinary research and development from basic science to clinical investigation in response to announcements of the programmatic needs of the Institute. The spectrum of activities comprises a multifaceted attack on a specific disease entity or biomedical problem area. 

NHLBI Centers of Research Program

Obligations (Dollars in Thousands)

Type of Center Period of Operation Prior to
FY 2012
FY 2012 Total to Date
NIH Centers for Population Health and Health Disparities (CPHHD) 2010– $20,067 $6,711 $26,778
Subtotal, CPHHD   20,067 6,711 26,778
Specialized Centers of Clinically Oriented Research (P50)        
Heart and Vascular Diseases Program        
Vascular Injury, Repair, and Remodeling (SCCOR) 2006– 71,403 2,831 74,234
Subtotal, Heart and Vascular Diseases Program   71,403 2,831 74,234
Lung Diseases Program        
Chronic Obstructive Pulmonary Disease (SCCOR) 2007– 53,556 2,578 56,134
Pulmonary Vascular Disease (SCCOR) 2007– 30,218 1,516 31,734
Subtotal, Lung Diseases Program   83,774 4,094 87,868
Subtotal, SCCORs (P50)   155,177 6,925 162,102
Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases (CADET) Phase I 2011– 9,001 8,850 17,851
Subtotal, CADET Phase I   9,001 8,850 17,851
NHLBI Translational Research Implementation Program (TRIP) 2012– 11,676 11,676
Subtotal, TRIP   11,676 11,676
Total, Centers of Research Program (P50)   $184,245 $34,162 $218,407

NIH Centers for Population Health and Health Disparities (CPHHD) (P50)

The purpose of this program is to create centers of transdisciplinary research that will evaluate the multilevel determinants of health disparities and devise interventions to reduce them. 

Obligations

Fiscal Year 2012 $6,711,003

Current Active Organizations and Grant Numbers

  1. University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina HL-105184
  2. Northeastern University
    Boston, Massachusetts HL-105185
  3. Johns Hopkins University
    Baltimore, Maryland HL-105187
  4. University of California, Los Angeles
    Los Angeles, California HL-105188
  5. Rush University Medical Center
    Chicago, Illinois HL-105189

Specialized Centers of Clinically Oriented Research (P50)

The NHLBI initiated the Specialized Centers of Research (SCOR) program in 1971 to encourage translational research converting basic science findings to the clinic in high priority areas. The SCOR concept emphasized multidisciplinary research (i.e., basic science and clinical investigations) on diseases relevant to the Institute's mission. In FY 2002, the NHLBI revised its SCOR program primarily on recommendation from the NHLBAC to place more emphasis on clinical research projects. The SCCOR program still requires clinical and basic scientists to work together on a unified theme, but also requires at least 50 percent of the projects to be clinical. The SCOR program ended in FY 2008.

A description of the SCCORs supported by the Institute follows.

Heart Diseases Program

Vascular Injury, Repair, and Remodeling

The purpose of this SCCOR is to stimulate interdependent clinical and multidisciplinary basic research projects that investigate molecular and cellular mechanisms of vascular injury, repair, and remodeling; promote patient-oriented research that will improve our ability to prevent, detect, characterize, manage, and treat vascular diseases; and develop the skills and research capabilities of new clinical investigators.

Obligations

Fiscal Year 2012 $2,830,751

Current Active Organization and Grant Number

  1. Beth Israel Deaconess Medical Center
    Boston, Massachusetts HL-083813

Lung Diseases Program

Chronic Obstructive Pulmonary Disease

The purpose of this SCCOR is to foster multidisciplinary research to accelerate progress in the diagnosis, prevention, and treatment of COPD.

Obligations

Fiscal Year 2012 $2,578,270

Current Active Organization and Grant Number

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania HL-084948

Pulmonary Vascular Disease

The objective of this SCCOR is to facilitate multidisciplinary research that proposes original hypotheses and applies cutting-edge approaches, including genomics and proteomics, to clinical issues in pulmonary vascular disease.

Obligations

Fiscal Year 2012 $1,515,534

Current Active Organization and Grant Number

  1. University of Colorado at Denver
    Denver, Colorado HL-084923

Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases (CADET) (P50)

The purpose of this program is to accelerate the development of novel agents for the diagnosis and treatment of lung diseases and sleep disordered breathing through the use of rational strategies based on fundamental pathobiologic processes. CADET I provides opportunities to explore potential targets for validation to determine which are amenable for development of mechanism-based modalities for direct clinical application in the prevention, diagnosis, and treatment of pulmonary diseases and sleep disordered breathing.

Obligations

Fiscal Year 2012 $8,850,080

Current Active Organizations and Grant Numbers

  1. Children's Hospital Medical Center Cincinnati
    Cincinnati, Ohio HL-107159
  2. University of Chicago
    Chicago, Illinois HL-107160
  3. Brigham and Women's Hospital
    Boston, Massachusetts HL-107165
  4. Brigham and Women's Hospital
    Boston, Massachusetts HL-107166
  5. University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina HL-107168
  6. Johns Hopkins University
    Baltimore, Maryland HL-107169
  7. University of Chicago
    Chicago, Illinois HL-107171
  8. University of Pittsburgh
    Pittsburgh, Pennsylvania HL-107172
  9. University of Michigan
    Ann Arbor, Michigan HL-107177
  10. Duke University
    Durham, North Carolina HL-107180
  11. University of Alabama, Birmingham
    Birmingham, Alabama HL-107181
  12. Johns Hopkins University
    Baltimore, Maryland HL-107182
  13. Washington University
    Saint Louis, Missouri HL-107183
  14. Johns Hopkins University
    Baltimore, Maryland HL-107185
  15. University of Texas Health Center at Tyler
    Tyler, Texas HL-107186
  16. University of Arizona
    Tucson, Arizona HL-107188
  17. Johns Hopkins University
    Baltimore, Maryland HL-107190
  18. University of California, San Francisco
    San Francisco, California HL-107191
  19. Brigham and Women's Hospital
    Boston, Massachusetts HL-107192

NHLBI Translational Research Implementation Program (C-TRIP) (P50)

The C-TRIP program was initiated in FY 2010 to accelerate the translation of promising new therapeutic interventions derived from fundamental research discoveries for the treatment and prevention of heart failure or arrhythmias. The program consists of two stages. Stage 1 focused on planning and developing clinical trials to determine the safety and efficacy of interventions to be conducted during Stage 2 of the overall program. Stage 2 TRIP studies are supported by the P50 mechanism.

Obligation

Fiscal Year 2012 $11,676,397

Current Active Organizations and Grant Numbers

  1. Fred Hutchinson Cancer Research Center
    Seattle, Washington HL-110787
  2. Tufts Medical Center
    Boston, Massachusetts HL-110789
  3. Dana-Farber Cancer Institute
    Boston, Massachusetts HL-110790
  4. Mount Sinai School of Medicine
    New York, New York HL-112324
  5. Brigham and Women's Hospital
    Boston, Massachusetts HL-112349

Translational Research Centers in Thrombotic and Hemostatic Disorders
(TRC-THD) (U54)

The purpose of this program is to enhance the translation of basic research discoveries that have the potential to improve the prevention, diagnosis, and treatment of thrombotic and hemostatic disorders. Investigators will advance early stage translational research, integrating applied and basic science, to move research discoveries toward clinical application.

Obligations

Fiscal Year 2012 $11,442,192

Current Active Organizations and Grant Numbers

  1. Beth Israel Deaconess Medical Center
    Boston, Massachusetts HL112302
  2. Washington University
    St. Louis, Missouri HL112303
  3. Duke University
    Durham, North Carolina HL112307
  4. Emory University
    Atlanta, Georgia HL112309
  5. University of Utah
    Salt Lake City, Utah HL112311

Centers for AIDS Research (P30) Program

The NHLBI, along with five other NIH Institutes, contributes to the support of six Centers for AIDS Research that were established to provide a multidisciplinary environment that promotes basic, clinical, behavioral, and translational research activities in the prevention, detection, and treatment of HIV infection and AIDS. Almost half of the patient population comes from minority groups.

Obligations

Fiscal Year 2012 $3,428,458

Current Active Organizations and Grant Numbers

  1. University of Washington
    Seattle, Washington AI-027757
  2. University of California, San Francisco
    San Francisco, California AI-027763
  3. University of Alabama, Birmingham
    Birmingham, Alabama AI-027767
  4. University of California, Los Angeles
    Los Angeles, California AI-028697
  5. Baylor University
    Houston, Texas AI-036211
  6. University of California, La Jolla
    La Jolla, California AI-036214
  7. Case Western Reserve University
    Cleveland, Ohio AI-036219
  8. University of Massachusetts, Worcester
    Worcester, Massachusetts AI-042845
  9. Miriam Hospital
    Providence, Rhode Island AI-042853
  10. University of Pennsylvania
    Philadelphia, Pennsylvania AI-045008
  11. Emory University
    Atlanta, Georgia AI-050409
  12. University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina AI-050410
  13. Yeshiva University
    New York, New York AI-051519
  14. Vanderbilt University
    Nashville, Tennessee AI-054999
  15. Harvard Medical School
    Boston, Massachusetts AI-060354
  16. Duke University
    Durham, North Carolina AI-064518
  17. University of Miami
    School of Medicine
    Coral Gables, Florida AI-073961
  18. University of Rochester
    Rochester, New York AI-078498
  19. Rush University Medical Center
    Chicago, Illinois AI-082151
  20. George Washington University
    Washington, DC AI-087714

Anchoring Metabolomic Changes to Phenotype Program (P20)

The purpose of this program is to gain mechanistic understanding of the molecular determinants that contribute to cardiovascular and lung disease phenotypes through metabolomic phenotyping of existing cohorts to help in predicting disease susceptibility, diagnosis, and risk stratification; assessing response to therapy; and assessing prognosis. The program will consist of two interacting components, a metabolomic component and a mechanistic component, each informing the other in an iterative manner.

Obligations

Fiscal Year 2012 $2,899,225

Current Active Organizations and Grant Numbers

  1. Weill Medical College of Cornell University
    New York, New York HL-113443
  2. Washington University
    St. Louis, Missouri HL-113444
  3. National Jewish Health
    Denver, Colorado HL-113445
  4. Emory University
    Atlanta, Georgia HL-113451
  5. Case Western Reserve University
    Cleveland, Ohio HL-113452

Back to Top

« Back

Next »

Fact Book Table of Contents

Twitter iconTwitterimage of external icon Facebook iconFacebookimage of external icon YouTube iconYouTubeimage of external icon Google+ iconGoogle+image of external icon